Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Bafna Pharmaceuticals Limited ( (IN:BAFNAPH) ).
Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24, 2025. This change led to the reconstitution of the Audit and Nomination & Remuneration Committees, ensuring continued compliance with regulatory requirements. The new committee members include Mr. Navin Kumar as Chairman of the Audit Committee and Mrs. Ravichandran Chitra as Chairperson of the Nomination and Remuneration Committee. Despite the changes, the board and its committees remain in compliance with applicable laws, maintaining stability in the company’s governance structure.
More about Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the manufacturing and distribution of pharmaceutical products. The company is based in Chennai, India, and is known for its commitment to quality and compliance with industry regulations.
Average Trading Volume: 1,035
Current Market Cap: 1.75B INR
Learn more about BAFNAPH stock on TipRanks’ Stock Analysis page.